The All-In-One Guru Screener can be used to find insider buys over the last week by clicking on the Insiders tab and changing the settings for All Insider Buying to “$1,000,000+” and duration to "September 2015."
According to the above filters, the following are the recent buys from company insiders during the second week of September.
On Sept. 10, Baker Bros. Advisors LP., which now holds more than 10% of outstanding shares of Aquinox Pharmaceuticals Inc. (AQXP) bought 2,480,032 shares of the company at the average price of $15.50 per share with a total cost of $38,440,500. Since then, the price of the stock has risen by 15.90%.
The company has an institutional ownership of 39% and an insider ownership of 1%.
The price of Aquinox has risen by 163% during the last 12 months and by 57% during the last five years. The company has negative returns, such as ROE of -68.08% and ROA -61.39%. Despite the very negative profitability, the company is out of debt.
Chuck Royce (Trades, Portfolio) is the main shareholder of the company with 1.05% of outstanding shares.
On Sept. 10, James Ketner, director and now 10% owner of Galenfeha Inc. (GLFH), bought 1,600,000 shares of the company at the average price of $0.17 per share with a total cost of $272,000. Since then, the price of the stock has doubled.
The company has an insider ownership of 50%.
The price of the company has dropped by 19% during the last 12 months. The company has negative returns with ROE of -79.12% and ROA -67.43%. Despite the very negative profitability, the company has a positive financial situation, with a cash to debt ratio of 2.57.
On Sept. 11, Riggio Leonard, who is chairman of the board and now 10% owner of Barnes & Noble Inc. (BKS) bought 1,000,000 shares of the company at the average price of $12.59 per share with a total cost of $12,590,000. Since then, the price of the stock has risen by 4.50%.
The company has an insider ownership of 17% and an institutional ownership of 89%.
The price of the company has dropped by 41% during the last 12 months and by 19% during the last five years. The company has null returns with ROE of -0.03% and ROA 0.82%, and these ratios are slightly above the average performance of the company during its recent history. Despite the very weak profitability, the company has a positive financial situation with no debt.
David Abrams (Trades, Portfolio) is the main shareholder of the company with 6.71% of outstanding shares, followed by Jim Simons (Trades, Portfolio) with 2.57% of outstanding shares and Joel Greenblatt (Trades, Portfolio) with 0.89%.
On Sept. 15, Felix Baker, who is director and 10% owner of Seattle Genetics Inc. (SGEN) bought 5,159,484 shares of the company at the average price of $42.56 per share with a total cost of $219,588,000. Since then, the price of the stock has risen by 10.70%.
The company has an insider ownership of 1% and an institutional ownership of 99%.
The price of the company has risen by 15% during the last 12 months and by 294% during the last five years. The company has negative returns with ROE of -53.03% and ROA -24.64%, and these ratios are above the average performance of the company during its recent history. Despite the very negative profitability, the company has no debt.
PRIMECAP Management (Trades, Portfolio) is the main shareholder with 9.49% of outstanding shares, followed by Columbia Wanger (Trades, Portfolio) with 1.88% and Manning & Napier Advisors Inc. with 0.20%.
On Sept. 17, Softbank Group Corp. bought more shares of Sprint Corp. (S). It bought 7,454,072 shares at the price of $4.77 with a total cost of $35,555,900. The investor is increasing its stake as reported in my previous articles (1,2,3,4,5).
Dodge & Cox is the main shareholder with 4.36% of outstanding shares, followed by PRIMECAP Management (Trades, Portfolio) with 0.51% and Larry Robbins (Trades, Portfolio) with 0.14%.
